Stock comparison
Novartis AG is 16.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.66 B vs $17.66 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NVS is larger
Novartis AG is 16.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.66 B vs $17.66 B).
Market value leader
NVS
Novartis AG is 16.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.66 B vs $17.66 B).
| Metric | BBIO | NVS |
|---|---|---|
| Market cap | $17.66 B | $294.66 B |
| US-listed rank | #665 | #46 |
| Revenue (latest FY) | $502.08M | - |
| Net margin | - | - |
| P/E (trailing FY) | - | - |
| SEC filings | 768 | 981 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Novartis AG is 16.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.66 B vs $17.66 B).
Full pages: BridgeBio Pharma, Inc. and Novartis AG, or browse the full rankings.